17 Jun Cyteir Therapeutics Announces Pricing of Initial Public Offering
The gross proceeds of the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Cyteir, are expected to be approximately $133 million excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on...